FIFarha Idrees

Farha Idrees

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farha Idrees has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    UBB as an early-stage potential biomarker for breast cancer via modulation of the ubiquitination pathway

    by Fatima Haider, Syeda Abiha Zehra Jaffari, Omema Saleem, Amber Ilyas, Nida Syed, Alex von Kriegsheim, Farha Idrees, Zehra Hashim

    Breast cancer ranks second leading cause of cancer related mortality worldwide, emphasizing the need of early diagnosis to improve therapeutic outcomes and disease-free survival. Ubiquitin, a highly conserved protein binds to target proteins to alter their functions, stability, and signaling activity. Multiple ubiquitination forms polyubiquitin chains, which may lead to proteasomal degradation and influence major signaling pathways. In this study, we demonstrate the potential of polyubiquitin B (UBB) as a promising biomarker for early stage breast cancer. We investigated the expression of UBB and ubiquitination pathway associated proteins in female breast cancer patients. Label free quantitative proteomic analysis revealed differentially expressed proteins, followed by network based analysis that identified key hub proteins. Furthermore, quantitative gene expression of hub proteins and other regulators of ubiquitination, demonstrated their alterations in breast cancer. Elevated expression of UBB was validated using competitive ELISA. Molecular docking between ubiquitin-specific protease 2 (USP2) and ubiquitin (PDB ID: 3NHE) in the presence of ML364 highlights the USP2 as potential drug target. Our findings establish a critical role for UBB and ubiquitination pathway proteins in breast carcinogenesis and disease progression. This study may provide valuable insights into early breast cancer diagnosis and supports the development of targeted therapeutic strategies.

  • GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer

    by Syeda Abiha Zehra Jaffari, Fatima Haider, Nida Syed, Amber Ilyas, Farha Idrees, Alex von Kriegsheim, Roopesh Krishnankutty, Syeda Nuzhat Nawab, Zehra Hashim

    Introduction: Breast cancer incidence and mortality have continued to rise over the past few decades. Despite advancements made in clinical research, the most imperative feature of breast cancer management is the diagnosis at the earliest stages. The current focus of the study is to identify and quantify differentially expressed oxidative stress-related proteins as putative early- stage markers for breast cancer. Methods: Normal and cancerous breast tissue samples (n = 40) were collected after approval from the institutional bioethics committee (IBC) with patient consent. A label-free proteomic approach was used to quantify oxidative stress-related proteins. Gene expression of GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a was quantified using RT-qPCR in all samples. Protein expression of PRDX2 and GSTP1 was further analyzed using immunohistochemistry. Results: The protein and gene expression of PRDX2, GSTP1, and HSP90 were significantly upregulated (p < 0.05) in cancerous samples as compared to normal. However, gene and protein expression of the transcription factor NFE2L2 was significantly downregulated (p < 0.05) in diseased samples. OncomiR-365a was also significantly upregulated (p < 0.05) in cancerous samples. Immunohistochemical analysis also confirmed the upregulated expression of GSTP1 and PRDX2 in cancer tissues. Discussion: Our study provides insight into the significant role of GSTP1, PRDX2, and NFE2L2 in the pathophysiology of the disease as early-stage breast cancer markers. It is suggested that altered expression of these key proteins could play a protective role in reducing the damage. Conclusion: It can be concluded that GSTP1, PRDX2, and NFE2L2 may serve as predictive early- stage markers for diagnosis and potential therapeutic targets for breast cancer.